PKM and myeloid sarcoma: While PKM was not associated with macrophages in the relevant literature, a study based on an EAE model (Seki et al. 2020) emphasizes the therapeutic potential of PKM2 activators in MS-like diseases since they change T-cell function, and shows how these activators change T-cell function.